Repurposing Auranofin, an Anti-Rheumatic Gold Compound, to Treat Acne Vulgaris by Targeting the NLRP3 Inflammasome

• Published in: Biomolecules & therapeutics 2020, 28(5), , pp.437-442
• Main Authors: Yang, Gabsik, Lee, Seon Joo, Kang, Han Chang, Cho, Yong-Yeon, Lee, Hye Suk, Zouboulis, Christos C, Han, Sin-Hee, Ma, Kyung-Ho, Jang, Jae-Ki, Lee, Joo Young
• Format: Article
• Language: English
• Subjects: Original; 약학
• ISSN: 1976-9148; 2005-4483
• DOI: 10.4062/biomolther.2020.004

Activation of the NLRP3 inflammasome is critical for host defense as well as the progression of inflammatory diseases through the production of the proinflammatory cytokine IL-1β, which is cleaved by active caspase-1. It has been reported that overactivation of the NLRP3 inflammasome contributes to the development and pathology of acne vulgaris. Therefore, inhibiting activation of the NLRP3 inflammasome may provide a new therapeutic strategy for acne vulgaris. In this study, we investigated whether auranofin, an anti-rheumatoid arthritis agent, inhibited NLRP3 inflammasome activation, thereby effectively treating acne vulgaris. Auranofin suppressed NLRP3 inflammasome activation induced by , reducing the production of IL-1β in primary mouse macrophages and human sebocytes. In a -induced acne mouse model, injection of into the ears of mice induced acne symptoms such as redness, swelling, and neutrophil infiltration. Topical application of auranofin (0.5 or 1%) to mouse ears significantly reduced the inflammatory symptoms of acne vulgaris induced by injection. Topical application of auranofin led to the downregulation of the NLRP3 inflammasome activated by in mouse ear skin. These results show that auranofin inhibits the NLRP3 inflammasome, the activation of which is associated with acne symptoms. The results further suggest that topical application of auranofin could be a new therapeutic strategy for treating acne vulgaris by targeting the NLRP3 inflammasome.